SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics
SWTX Price/Volume Stats
| Current price | $44.20 | 52-week high | $53.92 |
| Prev. close | $43.38 | 52-week low | $18.00 |
| Day low | $41.75 | Volume | 999,700 |
| Day high | $45.19 | Avg. volume | 1,097,333 |
| 50-day MA | $47.61 | Dividend yield | N/A |
| 200-day MA | $34.31 | Market Cap | 3.26B |
SWTX Stock Price Chart Interactive Chart >
SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Latest SWTX News From Around the Web
Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 a.m. PT. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https: |
SpringWorks Therapeutics announces closing of upsized public offering of common stockMore on SpringWorks Therapeutics |
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesSTAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in |
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common StockSTAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and |
SpringWorks Therapeutics Announces Proposed Public Offering of Common StockSTAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares |
SWTX Price Returns
| 1-mo | -11.78% |
| 3-mo | 4.27% |
| 6-mo | 104.53% |
| 1-year | 90.93% |
| 3-year | -40.23% |
| 5-year | N/A |
| YTD | 21.10% |
| 2023 | 40.33% |
| 2022 | -58.03% |
| 2021 | -14.53% |
| 2020 | 88.41% |
| 2019 | N/A |
Loading social stream, please wait...